Tofacitinib Citrate and GI obstruction

• Generic Name: tofacitinib
• Dosage Forms: n.a.
• Other Brand Names: Xeljanz, Xeljanz XR

Management of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate; can be used alone or in combination with methotrexate or other nonbiologic DMARDs (e.g., hydroxychloroquine, leflunomide, minocycline, sulfasalazine).

Concomitant use with biologic DMARDs, such as tumor necrosis factor (TNF) blocking agents (e.g., adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), interleukin-1 (IL-1) receptor antagonists (e.g., anakinra), anti-CD20 monoclonal antibodies (e.g., rituximab), selective costimulation modulators (e.g., abatacept), and anti-interleukin-6-receptor monoclonal antibodies (e.g., sarilumab, tocilizumab), not recommended.

Concomitant use with potent immunosuppressive agents (e.g., azathioprine, cyclosporine) also not recommended.

Management of active psoriatic arthritis in adults who have had an inadequate response or intolerance to methotrexate or other DMARDs.

Concomitant use with biologic DMARDs (see Rheumatoid Arthritis in Adults under Uses) or potent immunosuppressive agents (e.g., azathioprine, cyclosporine) not recommended.

Management of moderately to severely active ulcerative colitis in adults who have had an inadequate response or intolerance to TNF blocking agents.

Concomitant use with biologic therapies for ulcerative colitis or potent immunosuppressive agents (e.g., azathioprine, cyclosporine) not recommended.